Sensitivity and engineered resistance of myeloid leukemia cells to BRD9 inhibition
暂无分享,去创建一个
M. Koegl | Yutaka Suzuki | M. Pearson | Jae-seok Roe | Junwei Shi | C. Vakoc | G. Bader | S. Steurer | Jessica L. Minder | T. Gerstberger | Teresa Gottschamel | Laetitia J. Martin | D. McConnell | Anja F. Hohmann | D. Thompson | Thomas Gerstberger
[1] Andrew J. Bannister,et al. Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition. , 2016, Journal of medicinal chemistry.
[2] S. Knapp,et al. Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor , 2016, Journal of medicinal chemistry.
[3] S. Knapp,et al. Discovery of a Chemical Tool Inhibitor Targeting the Bromodomains of TRIM24 and BRPF , 2015, Journal of medicinal chemistry.
[4] Stefan Knapp,et al. Discovery and Characterization of GSK2801, a Selective Chemical Probe for the Bromodomains BAZ2A and BAZ2B , 2015, Journal of medicinal chemistry.
[5] K. Helin,et al. SWI/SNF Subunits SMARCA4, SMARCD2 and DPF2 Collaborate in MLL-Rearranged Leukaemia Maintenance , 2015, PloS one.
[6] John P. Overington,et al. The promise and peril of chemical probes. , 2015, Nature chemical biology.
[7] Parantu K. Shah,et al. The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies. , 2015, Cancer research.
[8] James E. Bradner,et al. Phthalimide conjugation as a strategy for in vivo target protein degradation , 2015, Science.
[9] C. Crews,et al. Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4. , 2015, Chemistry & biology.
[10] K. Wood,et al. NanoBRET--A Novel BRET Platform for the Analysis of Protein-Protein Interactions. , 2015, ACS chemical biology.
[11] A. Ciulli,et al. Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4 , 2015, ACS chemical biology.
[12] J. Kinney,et al. Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains , 2015, Nature Biotechnology.
[13] S. Knapp,et al. LP99: Discovery and Synthesis of the First Selective BRD7/9 Bromodomain Inhibitor** , 2015, Angewandte Chemie.
[14] M. Höss,et al. Small molecule inhibitors of bromodomain-acetyl-lysine interactions. , 2015, ACS chemical biology.
[15] Sumio Sugano,et al. Aberrant transcriptional regulations in cancers: genome, transcriptome and epigenome analysis of lung adenocarcinoma cell lines , 2014, Nucleic acids research.
[16] M. T. McCabe,et al. EZH2 as a potential target in cancer therapy. , 2014, Epigenomics.
[17] C. Vakoc,et al. A rationale to target the SWI/SNF complex for cancer therapy. , 2014, Trends in genetics : TIG.
[18] Julian Blagg,et al. Chemical biology approaches to target validation in cancer. , 2014, Current opinion in pharmacology.
[19] S. Knapp,et al. Discovery and Optimization of Small-Molecule Ligands for the CBP/p300 Bromodomains , 2014, Journal of the American Chemical Society.
[20] G. Crabtree,et al. Essential role of BRG, the ATPase subunit of BAF chromatin remodeling complexes, in leukemia maintenance. , 2014, Blood.
[21] Christof Fellmann,et al. An optimized microRNA backbone for effective single-copy RNAi. , 2013, Cell reports.
[22] Ming Yu,et al. Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation , 2013, Genes & development.
[23] J. Yokota,et al. A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1. , 2013, Cancer research.
[24] S. Orkin,et al. Targeted Disruption of the EZH2/EED Complex Inhibits EZH2-dependent Cancer , 2013, Nature chemical biology.
[25] G. Crabtree,et al. Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy , 2013, Nature Genetics.
[26] P. Clemons,et al. Target identification and mechanism of action in chemical biology and drug discovery. , 2013, Nature chemical biology.
[27] Yan Liu,et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations , 2012, Nature.
[28] Stefan Knapp,et al. The bromodomain interaction module , 2012, FEBS letters.
[29] A. Gingras,et al. Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family , 2012, Cell.
[30] H. Stunnenberg,et al. SS18 Together with Animal-Specific Factors Defines Human BAF-Type SWI/SNF Complexes , 2012, PloS one.
[31] Jun O. Liu,et al. Identification and validation of protein targets of bioactive small molecules. , 2012, Bioorganic & medicinal chemistry.
[32] S. Armstrong,et al. Polycomb repressive complex 2 is required for MLL-AF9 leukemia , 2012, Proceedings of the National Academy of Sciences.
[33] S. Lowe,et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia , 2011, Nature.
[34] Asher Mullard,et al. Reliability of 'new drug target' claims called into question , 2011, Nature Reviews Drug Discovery.
[35] A. Musacchio,et al. A general framework for inhibitor resistance in protein kinases. , 2011, Chemistry & biology.
[36] Ronald J. Moore,et al. Reversed‐phase chromatography with multiple fraction concatenation strategy for proteome profiling of human MCF10A cells , 2011, Proteomics.
[37] Clemens Vonrhein,et al. Data processing and analysis with the autoPROC toolbox , 2011, Acta crystallographica. Section D, Biological crystallography.
[38] D. Reinberg,et al. The Polycomb complex PRC2 and its mark in life , 2011, Nature.
[39] Christof Fellmann,et al. Toolkit for evaluating genes required for proliferation and survival using tetracycline-regulated RNAi , 2011, Nature Biotechnology.
[40] C. Rice,et al. Suppression of inflammation by a synthetic histone mimic , 2010, Nature.
[41] William B. Smith,et al. Selective inhibition of BET bromodomains , 2010, Nature.
[42] P. Emsley,et al. Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.
[43] Vincent B. Chen,et al. Correspondence e-mail: , 2000 .
[44] Ronghua Chen,et al. Digital transcriptome profiling using selective hexamer priming for cDNA synthesis , 2009, Nature Methods.
[45] G. Crabtree,et al. Understanding the Words of Chromatin Regulation , 2009, Cell.
[46] Christopher R. Vakoc,et al. DOT1L/KMT4 Recruitment and H3K79 Methylation Are Ubiquitously Coupled with Gene Transcription in Mammalian Cells , 2008, Molecular and Cellular Biology.
[47] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[48] J. Gebler,et al. Two-dimensional separation of peptides using RP-RP-HPLC system with different pH in first and second separation dimensions. , 2005, Journal of separation science.
[49] Ming-Ming Zhou,et al. Selective small molecules blocking HIV-1 Tat and coactivator PCAF association. , 2005, Journal of the American Chemical Society.
[50] K. Parker,et al. Multiplexed Protein Quantitation in Saccharomyces cerevisiae Using Amine-reactive Isobaric Tagging Reagents*S , 2004, Molecular & Cellular Proteomics.
[51] D. N. Perkins,et al. Probability‐based protein identification by searching sequence databases using mass spectrometry data , 1999, Electrophoresis.
[52] Lei Zeng,et al. Structure and ligand of a histone acetyltransferase bromodomain , 1999, Nature.
[53] Collaborative Computational,et al. The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.